{"id":61193,"date":"2015-11-07T08:00:20","date_gmt":"2015-11-07T13:00:20","guid":{"rendered":"http:\/\/1boringoldman.com\/?p=61193"},"modified":"2015-11-07T10:27:47","modified_gmt":"2015-11-07T15:27:47","slug":"how-quaint","status":"publish","type":"post","link":"https:\/\/1boringoldman.com\/index.php\/2015\/11\/07\/how-quaint\/","title":{"rendered":"how quaint&#8230;"},"content":{"rendered":"<div align=\"justify\" class=\"small\">These are some links to articles I&#8217;ve reviewed in the recent past &#8211; industry funded, professionally-ghost-written, clinical trials of the newer atypical antipsychotics published in highly ranked, peer reviewed, <em><font color=\"#200020\">academic<\/font><\/em> journals. There are some other things they share in common [I made it easy with my red highlighting]:<\/div>\n<ul><span class=\"small\">      <\/p>\n<li>\n<div align=\"justify\"><a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21676992\" target=\"_blank\">Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study.<\/a><\/div>\n<div align=\"justify\">by <strong><font color=\"#990000\">Meltzer HY<\/font><\/strong>, Cucchiaro J, Silva R, Ogasa M, Phillips D, Xu J, Kalali AH, Schweizer E, Pikalov A, and Loebel A.<\/div>\n<div align=\"justify\"><strong><font color=\"#004400\">American Journal of Psychiatry<\/font><\/strong>. 2011 168(9):957-67.<\/div>\n<\/li>\n<li>\n<div align=\"justify\"><a target=\"_blank\" href=\"http:\/\/ajp.psychiatryonline.org\/article.aspx?articleID=1763708\">Lurasidone Monotherapy in the Treatment of Bipolar I Depression: A Randomized, Double-Blind, Placebo-Controlled Study<\/a><\/div>\n<div align=\"justify\">by   Antony Loebel, M.D. Josephine Cucchiaro, Ph.D. Robert Silva, Ph.D. Hans Kroger, M.P.H., M.S. Jay Hsu, Ph.D. Kaushik Sarma, M.D. <strong><font color=\"#990000\">Gary Sachs, M.D. <\/font><\/strong><\/div>\n<div align=\"justify\"><strong><font color=\"#004400\">American Journal of Psychiatry<\/font><\/strong>. 2014 171:160&ndash;168.<\/div>\n<\/li>\n<li>\n<div align=\"justify\"><a target=\"_blank\" href=\"http:\/\/ajp.psychiatryonline.org\/Article.aspx?ArticleID=1763709\">Lurasidone  as Adjunctive Therapy With Lithium or Valproate for the Treatment of  Bipolar I Depression: A Randomized, Double-Blind, Placebo-Controlled  Study<\/a><\/div>\n<div align=\"justify\">by    Antony Loebel, M.D. Josephine Cucchiaro, Ph.D. Robert Silva, Ph.D. Hans Kroger, M.P.H., M.S. Kaushik Sarma, M.D. Jane Xu, Ph.D. <strong><font color=\"#990000\">Joseph R. Calabrese, M.D.<\/font><\/strong><\/div>\n<div align=\"justify\"><strong><font color=\"#004400\">American Journal of Psychiatry<\/font><\/strong>. 2014 171:169&ndash;177.<\/div>\n<\/li>\n<li>\n<div align=\"justify\"><a target=\"_self\" href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25882325\">Efficacy   and Safety of Brexpiprazole for the Treatment of Acute Schizophrenia: A   6-Week Randomized, Double-Blind, Placebo-Controlled Trial<\/a><\/div>\n<div align=\"justify\">by <strong><font color=\"#990000\">Correll CU<\/font><\/strong>, Skuban A, Ouyang J, Hobart M, Pfister S, McQuade RD, Nyilas M, Carson WH, Sanchez R, and Eriksson H.<\/div>\n<div align=\"justify\"><strong><font color=\"#004400\">American Journal of Psychiatry<\/font><\/strong>. 2015 172[9]:820-821. <\/div>\n<\/li>\n<li>\n<div align=\"justify\"><a target=\"_self\" href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25682550\">A   multicenter, randomized, double-blind, controlled phase 3 trial of   fixed-dose brexpiprazole for the treatment of adults with acute   schizophrenia.<\/a><\/div>\n<div align=\"justify\">by <strong><font color=\"#990000\">Kane JM<\/font><\/strong>, Skuban, Ouyang, Hobart, Pfister, McQuade, Nyilas, Carson, Sanchez, and Eriksson.<\/div>\n<div align=\"justify\"><strong><font color=\"#0033ff\">Schizophrenia Research<\/font><\/strong>. 2015 164[1-3]:127-35.<\/div>\n<\/li>\n<p>       <\/span><\/ul>\n<div align=\"justify\" class=\"small\">Each article has <strong><font color=\"#200020\">only one<\/font><\/strong> academic author [all of whom have conflicts of interest specific to the drug being studied]. So <strong><font color=\"#200020\">only five<\/font><\/strong> of the forty-four authors are academics. Since the studies were conducted by Contract Research Organizations at multiple Clinical Research Centers all over the world, it is also even possible that none of the forty-four listed authors ever met a one of the subjects involved in these studies.   <\/div>\n<p align=\"justify\" class=\"small\">I&#8217;ve been thinking about this ever since we wrote the RIAT 329 article. It felt odd to me that our group was writing about subjects we&#8217;ve never seen. But then it occurred to me that it&#8217;s the standard in a lot of the Contract Research Organization managed studies. The other thing that occurred to me over and over was that our group had no direct contact with any of the twenty-two <em><font color=\"#200020\">authors<\/font><\/em> of the original Paxil Study 329 &#8211; only with the sponsoring pharmaceutical company. And reading through the Clinical Study Report, it was obviously written by and analyzed by the sponsor. Even the professional ghost-writer worked off of some version of a summary document prepared by the sponsor. I would suspect that the same is true about the articles above. I guess we&#8217;re just so used to the primacy of the sponsors, in spite of the fact that we anachronistically still refer to these articles as &quot;<font color=\"#200020\">Kane et al<\/font>&quot; or &quot;<font color=\"#200020\">Keller et al<\/font>&quot; [<font color=\"#200020\">how quaint!<\/font>].<\/p>\n<div align=\"justify\" class=\"small\"><img decoding=\"async\" width=\"90\" hspace=\"4\" border=\"0\" align=\"right\" src=\"http:\/\/1boringoldman.com\/images\/md-ticket-1.gif\" \/>It just doesn&#8217;t seem to register anymore that this class of articles reporting clinical trials is published in <em><font color=\"#200020\">academic<\/font><\/em> journals, but it has no real connection to anything &quot;<em><font color=\"#200020\">academic<\/font><\/em>.&quot; I&#8217;ve referred to the authors highlighted in red as &quot;<font color=\"#200020\">tickets<\/font>,&quot; as if their function is to certify admission to the journals. I recently suggested facetiously in <a href=\"http:\/\/1boringoldman.com\/index.php\/2015\/10\/29\/maybe-nowhere\/\" target=\"_blank\">maybe nowhere&hellip;<\/a> that&#8230;<\/div>\n<blockquote>\n<div align=\"justify\"> It would be fine with me if there were a specific journal for that kind of paper &ndash; the <em><font color=\"#200020\">Journal of Industry Financed Reviews and Clinical Trials in Psychopharmacology<\/font><\/em>&#8230; If the peer reviewed academic  journals absolutely need the revenue, they could at least put these  articles in a labeled, dedicated section of their publications with a  heading [I suggest <em><font color=\"#200020\">Industry Financed Reviews and Clinical Trials in Psychopharmacology<\/font><\/em>].  <\/div>\n<\/blockquote>\n<div align=\"justify\" class=\"small\">&#8230;but maybe I should have taken myself more seriously. I&#8217;m beginning to wonder if we are perpetuating the myth that these articles are the productions of an ethical academic author or set of authors. Perhaps we should insist that they be clearly identified as non-academic industrial productions &#8211; which is what they are &#8211; and published in a section of their own that makes that fact crystal clear. Why not? It&#8217;s the truth&#8230; <\/div>\n","protected":false},"excerpt":{"rendered":"<p>These are some links to articles I&#8217;ve reviewed in the recent past &#8211; industry funded, professionally-ghost-written, clinical trials of the newer atypical antipsychotics published in highly ranked, peer reviewed, academic journals. There are some other things they share in common [I made it easy with my red highlighting]: Lurasidone in the treatment of schizophrenia: a [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_forum_subforum_count":0,"footnotes":""},"categories":[5],"tags":[],"class_list":["post-61193","post","type-post","status-publish","format-standard","hentry","category-opinion"],"_links":{"self":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/61193","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/comments?post=61193"}],"version-history":[{"count":19,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/61193\/revisions"}],"predecessor-version":[{"id":61206,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/61193\/revisions\/61206"}],"wp:attachment":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/media?parent=61193"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/categories?post=61193"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/tags?post=61193"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}